

**TGFBR2 (pS225) Antibody**  
**Purified Rabbit Polyclonal Antibody (Pab)**  
**Catalog # AP51559**

**Specification**

---

**TGFBR2 (pS225) Antibody - Product Information**

|                   |                          |
|-------------------|--------------------------|
| Application       | <b>WB, IHC-P, E</b>      |
| Primary Accession | <a href="#">P37173</a>   |
| Reactivity        | <b>Human, Mouse, Rat</b> |
| Host              | <b>Rabbit</b>            |
| Clonality         | <b>Polyclonal</b>        |
| Calculated MW     | <b>65 KDa</b>            |

**TGFBR2 (pS225) Antibody - Additional Information**

**Gene ID** 7048

**Other Names**

TGF-beta receptor type-2, TGFR-2, TGF-beta type II receptor, Transforming growth factor-beta receptor type II, TGF-beta receptor type II, TbetaR-II, TGFBR2

**Format**

0.01M PBS, pH 7.2, 0.09% (W/V) Sodium azide, Glycerol 50%

**Storage**

Store at -20 °C. Stable for 12 months from date of receipt

**TGFBR2 (pS225) Antibody - Protein Information**

**Name** TGFBR2

**Function**

Transmembrane serine/threonine kinase forming with the TGF- beta type I serine/threonine kinase receptor, TGFBR1, the non- promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to the cytoplasm and thus regulates a plethora of physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. The formation of the receptor complex composed of 2 TGFBR1 and 2 TGFBR2 molecules symmetrically bound to the cytokine dimer results in the phosphorylation and activation of TGFBR1 by the constitutively active TGFBR2. Activated TGFBR1 phosphorylates SMAD2 which dissociates from the receptor and interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the nucleus where it modulates the transcription of the TGF-beta-regulated genes. This constitutes the canonical SMAD-dependent TGF-beta signaling cascade. Also involved in non-canonical, SMAD-independent TGF-beta signaling pathways.

**Cellular Location**

Cell membrane; Single-pass type I membrane protein. Membrane raft

## **TGFBR2 (pS225) Antibody - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

## **TGFBR2 (pS225) Antibody - Images**

## **TGFBR2 (pS225) Antibody - Background**

Transmembrane serine/threonine kinase forming with the TGF-beta type I serine/threonine kinase receptor, TGFBR1, the non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to the cytoplasm and is thus regulating a plethora of physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. The formation of the receptor complex composed of 2 TGFBR1 and 2 TGFBR2 molecules symmetrically bound to the cytokine dimer results in the phosphorylation and the activation of TGFBR1 by the constitutively active TGFBR2. Activated TGFBR1 phosphorylates SMAD2 which dissociates from the receptor and interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the nucleus where it modulates the transcription of the TGF-beta-regulated genes. This constitutes the canonical SMAD-dependent TGF-beta signaling cascade. Also involved in non-canonical, SMAD-independent TGF-beta signaling pathways.

## **TGFBR2 (pS225) Antibody - References**

Lin H.Y., et al. Cell 68:775-785(1992).  
Lin H.Y., et al. Cell 70:1069-1069(1992).  
Nikawa J., et al. Gene 149:367-372(1994).  
Takenoshita S., et al. Genomics 36:341-344(1996).  
Lu S.-L., et al. Cancer Res. 56:4595-4598(1996).